These findings further underscore the prognostic significance of CD8+ T cells in NSCLC and the association between achieving potent antitumor effects by targeting the PD1 inhibition pathway, especially when combining PD1 blockade with anti-IL-6 antibodies. The gene discussed is IL6; the disease is non-small cell lung carcinoma.